Beam Therapeutics Inc.

NASDAQ: BEAM · Real-Time Price · USD
17.64
0.12 (0.68%)
At close: Aug 14, 2025, 3:59 PM
17.74
0.57%
After-hours: Aug 14, 2025, 07:53 PM EDT

Beam Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
63.52M 377.71M 60.92M 51.84M
Cost of Revenue
n/a 437.38M 22.58M 16.44M
Gross Profit
63.52M -59.67M 38.34M 35.4M
Operating Income
-415.57M -176.49M -338.48M -392.46M
Interest Income
n/a n/a 15.3M 9K
Pretax Income
-376.7M -131.16M -260.18M -370.64M
Net Income
-376.74M -132.53M -263.59M -341.36M
Selling & General & Admin
111.53M 116.81M 87.81M 57.22M
Research & Development
367.56M 437.38M 311.59M 387.09M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
479.09M 554.19M 399.4M 444.31M
Interest Expense
n/a n/a 15.3M 9K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
479.09M 554.19M 399.4M 444.31M
Income Tax Expense
39K 1.37M 3.41M -29.28M
Shares Outstanding (Basic)
82.31M 77.15M 70.02M 64.23M
Shares Outstanding (Diluted)
82.31M 77.15M 70.02M 64.23M
EPS (Basic)
-4.58 -1.72 -3.76 -5.31
EPS (Diluted)
-4.58 -1.72 -3.76 -5.31
EBITDA
-383.98M -156.47M -324.33M -392.46M
EBIT
-415.57M -176.49M -338.48M -370.63M
Depreciation & Amortization
31.59M 20.01M 22.58M 16.44M